Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Background Despite higher thromboembolism risk, women with atrial fibrillation have lower
oral anticoagulation (OAC) use compared to men. The influence of the CHA 2 DS 2‐VAS c …

Objectives The aim was to perform a review of the efficacy and safety of new oral
anticoagulants (NOAs) in the management of venous thromboembolism (VTE). Methods …

Arterial and venous thromboembolism are leading causes of morbidity and mortality around
the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight …

Novel oral anticoagulants (NOACs)(rivaroxaban, dabigatran, apixaban) have been
approved by international regulatory agencies to treat atrial fibrillation and venous …

You are seeing Mr Roberts, a 69-year-old retired office manager referred from the
emergency department for treatment of atrial fibrillation (AF). He presented the previous …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations.
Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been …